Market revenue in 2023 | USD 189.0 million |
Market revenue in 2030 | USD 314.4 million |
Growth rate | 7.5% (CAGR from 2023 to 2030) |
Largest segment | Bioavailability & bioequivalence studies |
Fastest growing segment | Bioavailability & Bioequivalence Studies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.4% in 2023. Horizon Databook has segmented the U.S. cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. accounts for the highest share of the global cell & gene therapy bioanalytical testing services market, as many pharmaceutical and biotechnology companies operate in this country. Increasing R&D investments and growing partnerships & collaborations among academic institutions, biopharmaceutical corporations, & CROs are contributing to the growth of cell and gene therapy bioanalytical testing services.
These partnerships promote innovation and market growth by facilitating information sharing, resource access, and common infrastructure for bioanalytical testing.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into U.S. cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account